Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Status:
Completed
Trial end date:
2020-08-27
Target enrollment:
Participant gender:
Summary
Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that
remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters"
let protein get into the kidney.
FSGS is a serious condition that can lead to kidney failure. The only treatment for kidney
failure is dialysis or kidney transplant.
Proteinuria means too much protein came through the kidneys into the urine.
If the doctor cannot figure out what is causing the problem, it is primary (idiopathic) FSGS.
This kind of FSGS is very hard to treat.
This study will test Acthar in patients with this condition who have not responded to other
treatments. It primarily investigates how well the therapy is tolerated by the patients and
how well they respond to this treatment.